



IACH

The 5th Annual Meeting of the International Academy for Clinical Hematology

(IACH) **Virtual Event**

September 22-24, 2022

www.iachlive.cme-congresses.com

Faculty disclosures report

The IACH 2022 Meeting seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of IACH 2022 participants. In doing so, the IACH 2022 Meeting recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The IACH 2022 Meeting requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The IACH 2022 Meeting considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the IACH 2022 Meeting of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the IACH 2022 Meeting of CME based on the CME providers of the Meeting.

All IACH 2022 Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The IACH 2022 Meeting defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

IACH 2022 Financial Disclosure Codes

Type of affiliation / financial interest	Code
Receipt of grants/research supports:	S
Receipt of consultation / advisory board / employment fees:	C
Lecture and/or honoraria fees:	L
Stock shareholder or equity owner:	O
Patents/royalties:	P
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

Disclosure Information

Financial interest disclosures from program members and others in a position for control content



IACH

The 5th Annual Meeting of the International Academy for Clinical Hematology

(IACH) **Virtual Event**

September 22-24, 2022

www.iachlive.cme-congresses.com

Ali Bazarbachi

Nothing to declare

Eileen Boyle

Nothing to declare

Eolia Brissot

S Novartis, Pfizer

C Astellas, Novartis, Jazz

L Astellas, Alexion, Jazz, Gilead, MSD, Keocyt, Amgen

Nelson Chao

Nothing to declare

Bhagirathbhai Dholaria, USA

S Takeda, Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen

C Jazz, Gamida Cell, MJH BioScience, Arivan Research, BEAM therapeutics, Janssen

Other Editorship: Wiley, HemOnc.Org

Brian Engelhardt

Nothing to declare

Robin Foà

L Amgen, Novartis, Astra Zeneca

Sebastian Giebel

C Amgen, Novartis, Pfizer

L Amgen, Novartis, Pfizer, Angelini, Servier

Christian Gisselbrecht

Nothing to declare

Olivier Hermine

Nothing to declare

Christopher Hourigan

S Sellas (NIH CRADA to Laboratory)

Elias Jabbour

Nothing to declare

Tania Jain

S Institutional research support from CTI Biopharma, Syneos Health, Incyte

C Advisory board participation with Care Dx, BMS, Incyte, AbbVie and CTI

Tapan Kadia

S Astra Zeneca, BMS, Celgene, Cellenkos, Cyclacel, Detla-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron

C Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier

L Cure, Genzyme, Hikma



IACH

The 5th Annual Meeting of the International Academy for Clinical Hematology

(IACH) **Virtual Event**

September 22-24, 2022

www.iachlive.cme-congresses.com

Adetola Kassim

Nothing to declare

Arnon Kater

S AbbVie, Roche/Genentech, Janssen, Astra Zeneca, BMS
C, L AbbVie, Roche/Genentech, Janssen, Astra Zeneca, BMS, LAVA

Mohamed Kharfan-Dabaja

Nothing to declare

Per Ljungman

S,C MSD
L Pfizer, Moderna, MSD

Jaroslawn Maciejewski

Nothing to declare

Giovanni Martinelli

Nothing to declare

Maria Victoria Mateos

L Janssen, Celgene, Takeda, Amgen, GSK, AbbVie, Pfizer, Regeneron, Roche, Sanofi, Oncopeptides, Seagen

Mohamad Mohty

C Janssen, Sanofi
L Janssen, Sanofi, Amgen, Takeda, BMS, Pfizer

Philippe Moreau

C, L Janssen, Amgen, Celgene, Sanofi, Oncopeptides, GSK, Boehringer Ingelheim, Takeda, Clinical Care

Arnon Nagler

Nothing to declare

Naveen Pemmaraju

S Sager Strong Foundation
C AbbVie, Aptitude Health, Astellas Pharma US Inc., Blueprint Medicines, BMS, Celgene, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI, Dava Oncology, Immunogen, Incyte, Intellisphere LLC, Novartis AG, Novartis Pharmaceuticals Corp., OnLive, Patient Power, PharmaEssentia, Protagonist Therapeutics, Total CME, Cancer.NET, CareDx, CTI, EUSA Pharma, Pacylex
L AbbVie, Aplastic Anemia & MDS International Foundation, Curio Science LLC, Dava Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, Physician Education Resource (PER), Postgraduate Institute for Medicine, Stemline Therapeutics
O Karger Publishers
Other Board of Directors: Dan's House of Hope

Giuseppe Saglio

Nothing to declare



IACH

The 5th Annual Meeting of the International Academy for Clinical Hematology

(IACH) **Virtual Event**

September 22-24, 2022

www.iachlive.cme-congresses.com

Valeria Santini

C AbbVie, BMS, Geron, Gilead, Menarini, Novartis, Otsuka, Servier, Syros, Takeda
L BMS, Novartis

Yogen Saunthararajah

Nothing to declare

Bipin Savani

Nothing to declare

Phillip Scheinberg

C,L Novartis

Christoph Schmid

Nothing to declare

Jordi Sierra

S Jazz, Astellas
C,L AbbVie, Pfizer, Jazz, Astellas

Anna Sureda

C Takeda, BMS/Celgene, MSD, Gilead Kite, Novartis, Sanofi, Janssen, Roche, GenMab, Pierre Fabre, Astra Zeneca
L Takeda, BMS/Celgene, MSD, Novartis, Gilead Kite, GenMab, Pierre Fabre

Catherine Wu

S Pharmacyclics
O BioNTech

Ibrahim Yakoub-Agha

Nothing to declare

Amer Zeidan

S Celgene, BMS, AbbVie, Pfizer, Boehringer Ingelheim, Trovogene, Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, Amgen, Otsuka, Astex, Medimmune, Astra Zeneca, ADC Therapeutics
C,L Celgene, BMS, AbbVie, Pfizer, Boehringer Ingelheim, Trovogene, Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, Amgen, Otsuka, Jazz, Agios, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, Beyondspring, Gilead, Kura, Tyme, Janssen, Syndax, Geron, Ionis, Epizyme